Navigation Links
Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/3/2011

mparable GAAP measures is provided in the accompanying table entitled "Reconciliation of GAAP to Non-GAAP Net Income (Loss)."

Revenue from Collaboration AgreementGlobal Nexavar net sales, which are recorded by Onyx's collaborator, Bayer HealthCare Pharmaceuticals Inc., or Bayer, were $245.7 million for the second quarter 2011, an increase of $9.6 million, or 4%, compared to $236.1 million for the same period in 2010. Onyx and Bayer are marketing and developing Nexavar® (sorafenib) tablets, an anticancer therapy currently approved for the treatment of unresectable liver cancer and advanced kidney cancer in over 100 countries worldwide.

For the second quarter 2011, Onyx reported total revenue from collaboration agreement of $68.0 million compared to $68.8 million for the same period in 2010.

Operating ExpensesOnyx recorded research and development expenses of $63.0 million in the second quarter 2011 compared to $43.3 million for the same period in 2010. The increase in research and development expense was primarily due to investments in the development of carfilzomib, particularly the Phase 3 ASPIRE and FOCUS trials.  

Selling, general and administrative expenses were $38.2 million in the second quarter 2011, compared to $26.6 million for the same period in 2010. Higher selling, general and administrative expenses between periods were primarily due to planned increases in employee headcount and related costs, legal costs, and selected pre-launch spending for carfilzomib.

Onyx recorded $5.8 million of non-cash contingent consideration expense in the second quarter 2011 associated with changes in the fair value of the liability for contingent consideration recorded for the potential milestone payments under the Proteolix acquisition.

As a result of consolidation of its facilities, Onyx ceased the use of facilities it previously occupied in Emeryville and in South San Francisco, California. In connect
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
2. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
4. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
5. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
6. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
9. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Osteotech, Inc. (Nasdaq: OSTE ), a leader in ... announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products ... Society (NASS) 2009 Annual Meeting, taking place November 10th through ... been used in 40 spinal surgeries in the ...
... Inc. (Nasdaq: VVUS ) today announced that Timothy Morris, chief ... Lazard Capital Markets 6th Annual Healthcare Conference. , The VIVUS presentation ... on Wednesday, November 18, 2009 at 1:45 p.m. ET. A ... at http://ir.vivus.com . , About VIVUS ...
Cached Medicine Technology:Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 2Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 3Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 4Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 5VIVUS to Present at Lazard Capital Markets Healthcare Conference 2
(Date:8/31/2015)... , ... August 31, 2015 , ... ... introduces the Talent Management Division , a department devoted to helping organizations ... department. Talent management goes beyond selection, and The Brooks Group believes in offering ...
(Date:8/31/2015)... ... 2015 , ... According to book reviewer Angie Santangeloon , Dr. ... Cancer is an excellent resource for everyone since one in three persons will ... in explaining what cancer is in a easy to understand medically accurate way. The ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... excited to establish its first Digital Hub in North America, now open in ... selecting Florida,” stated Founder and CEO John Campbell. “Jacksonville’s lifestyle, waterways and beautiful ...
(Date:8/31/2015)... CO (PRWEB) , ... August 31, 2015 , ... Adult ... potential Denver area dermatology patients of the treatments and services available to ... patients by utilizing an innovative and ‘responsive design’ that allows visitors to view the ...
(Date:8/31/2015)... , ... August 31, 2015 , ... TheHardwareCity.com is pleased ... tools set . , These home repair tool sets are manufactured by Allied Tools. ... around the house. The tri-fold tool set allows yard and house work to be ...
Breaking Medicine News(10 mins):Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2Health News:Global Digital Opens USA Digital Agency Hub 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3Health News:TheHardwareCity.com Now Offering Allied 49032 25 Piece Tri-Fold Tool Set 2
... , NANJING, China, June 19 ... a leading manufacturer and supplier of branded generic and,innovative ... annual,report on Form 20-F for the year ended December ... 18, 2009. The annual report can be accessed on,the ...
... ... will be introducing ten (10) new products at the 26th Annual ASMBS scheduled for June ... ... introducing ten (10) new products at the 26th Annual ASMBS scheduled for June 21-26 in ...
... Georgia facility to offer new choice in cancer treatment with fully ... 18 Cancer Treatment Centers of America (CTCA) announced today that ... cancer treatment hospital that will serve patients in the Southeast and ... View the Multimedia News Release, go to: http://www.prnewswire.com/mnr/cancercenter/38837 ...
... traumatic brain injury (TBI) has reached critical levels in ... of Neurotrauma focuses on the intensive efforts to ... the cause and effects of explosive blast TBI. This ... peer-reviewed journal published by Mary Ann Liebert, Inc., is ...
... , Senator John D. Rockefeller IV and Senator Bob Corker ... YORK, June 18 The American Society of Interventional ... All Schedules Prescription Electronic Reporting (NASPER) Act has received ... Virginia and Senator Bob Corker of Tennessee. , ...
... (Nasdaq: MEDQ ) has announced it has added ... Chief Information Officer. , , "As CIO, ... and development resources are aligned with its strategic and operational ... for profitable revenue and market share growth," says Peter Masanotti, ...
Cached Medicine News:Health News:Bariatric Advantage to Introduce Ten (10) New Products at ASMBS 2Health News:VIDEO: Cancer Treatment Centers of America Selects Site in GA for Proposed Hospital Serving Patients in Southeast 2Health News:Traumatic brain injury caused by exposure to explosive blast presents critical challenge 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 3Health News:MedQuist Adds Kevin Piltz as New Chief Information Officer 2
... For many years, anyone using the Farnsworth D15, ... complained about how patients cannot avoid touching the ... kits become unusable. Further, the disks are very ... for these products in order to solve these ...
... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
... is as easy as 1-2-3: just three simple ... satisfaction with rapid information before they leave your ... with the appropriate therapy; no more follow-up appointments ... Strep A Test is a rapid immunochromatographic assay ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Medicine Products: